Does the media favor ROIV or CGON?

In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 14 mentions for Roivant Sciences and 8 mentions for CG Oncology. Roivant Sciences' average media sentiment score of 1.21 beat CG Oncology's score of 1.07 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.77% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.77% -5.93% CG Oncology N/A -23.33% -22.24%

Does the media favor BNTX or CGON?

In the previous week, BioNTech had 13 more articles in the media than CG Oncology. MarketBeat recorded 21 mentions for BioNTech and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat BioNTech's score of 0.09 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INSM or CGON?

CG Oncology has lower revenue, but higher earnings than Insmed. CG Oncology is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.39 -$1.28B -$5.75 N/A CG Oncology $4.04M 1,581.05 -$160.99M -$2.33 N/A

Is INSM or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Insmed's net margin of -144.44%. CG Oncology's return on equity of -23.33% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% CG Oncology N/A -23.33% -22.24%

Does the media favor INSM or CGON?

In the previous week, Insmed had 4 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for Insmed and 8 mentions for CG Oncology. Insmed's average media sentiment score of 1.27 beat CG Oncology's score of 1.07 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Moderna's net margin of -141.43%. CG Oncology's return on equity of -23.33% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% CG Oncology N/A -23.33% -22.24%

Does the media favor MRNA or CGON?

In the previous week, Moderna had 57 more articles in the media than CG Oncology. MarketBeat recorded 65 mentions for Moderna and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat Moderna's score of 0.47 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 23 Very Positive mention(s) 7 Positive mention(s) 14 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or VTRS more profitable?

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Viatris -2.04% 19.04% 7.62%

Does the media favor CGON or VTRS?

In the previous week, CG Oncology and CG Oncology both had 8 articles in the media. CG Oncology's average media sentiment score of 1.07 beat Viatris' score of 0.36 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CG Oncology (CGON) Competitors

$72.42 +1.02 (+1.43%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$71.46 -0.97 (-1.33%)

As of 06:10 AM Eastern

Compare

CGON vs. ROIV, BNTX, INSM, MRNA, and VTRS

Should you buy CG Oncology stock or one of its competitors? MarketBeat compares CG Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CG Oncology include Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS).

How does CG Oncology compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential downside of 2.92%. CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 12.85%. Given CG Oncology's higher possible upside, analysts clearly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 14 mentions for Roivant Sciences and 8 mentions for CG Oncology. Roivant Sciences' average media sentiment score of 1.21 beat CG Oncology's score of 1.07 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
CG Oncology	N/A	-23.33%	-22.24%

CG Oncology has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,012.92	-$299.77M	-$0.60	N/A
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A

Summary

Roivant Sciences beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does CG Oncology compare to BioNTech?

BioNTech (NASDAQ:BNTX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

BioNTech currently has a consensus price target of $127.81, indicating a potential upside of 38.66%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 12.85%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, BioNTech had 13 more articles in the media than CG Oncology. MarketBeat recorded 21 mentions for BioNTech and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat BioNTech's score of 0.09 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than BioNTech. CG Oncology is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	8.80	-$1.29B	-$7.83	N/A
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.77% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.77%	-5.93%
CG Oncology	N/A	-23.33%	-22.24%

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Summary

BioNTech beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Insmed?

Insmed (NASDAQ:INSM) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

26.6% of CG Oncology shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Insmed had 4 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for Insmed and 8 mentions for CG Oncology. Insmed's average media sentiment score of 1.27 beat CG Oncology's score of 1.07 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a net margin of 0.00% compared to Insmed's net margin of -144.44%. CG Oncology's return on equity of -23.33% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
CG Oncology	N/A	-23.33%	-22.24%

CG Oncology has lower revenue, but higher earnings than Insmed. CG Oncology is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.39	-$1.28B	-$5.75	N/A
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A

Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Insmed currently has a consensus price target of $209.35, suggesting a potential upside of 111.42%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 12.85%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Insmed beats CG Oncology on 9 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Moderna?

Moderna (NASDAQ:MRNA) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

In the previous week, Moderna had 57 more articles in the media than CG Oncology. MarketBeat recorded 65 mentions for Moderna and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat Moderna's score of 0.47 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	23 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna presently has a consensus target price of $42.13, suggesting a potential downside of 25.11%. CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 12.85%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology has lower revenue, but higher earnings than Moderna. CG Oncology is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	10.16	-$2.82B	-$7.99	N/A
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A

75.3% of Moderna shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CG Oncology has a net margin of 0.00% compared to Moderna's net margin of -141.43%. CG Oncology's return on equity of -23.33% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
CG Oncology	N/A	-23.33%	-22.24%

Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

CG Oncology beats Moderna on 9 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Viatris?

CG Oncology (NASDAQ:CGON) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

CG Oncology has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A
Viatris	$14.56B	1.41	-$3.51B	-$0.26	N/A

In the previous week, CG Oncology and CG Oncology both had 8 articles in the media. CG Oncology's average media sentiment score of 1.07 beat Viatris' score of 0.36 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

CG Oncology currently has a consensus target price of $81.73, suggesting a potential upside of 12.85%. Viatris has a consensus target price of $17.50, suggesting a potential downside of 0.85%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Viatris	-2.04%	19.04%	7.62%

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CG Oncology beats Viatris on 9 of the 15 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.30B	$3.57B	$6.86B	$12.98B
Dividend Yield	N/A	3.77%	2.60%	9.79%
P/E Ratio	-31.08	7.68	280.40	25.25
Price / Sales	1,581.05	1,175.61	560.36	77.68
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	7.76	17.07	12.94	6.09
Net Income	-$160.99M	-$12.52M	$3.49B	$347.95M
7 Day Performance	-0.84%	2.34%	2.43%	3.08%
1 Month Performance	4.56%	-5.13%	-2.86%	-3.01%
1 Year Performance	186.36%	52.38%	75.40%	20.49%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.7507 of 5 stars	$72.42 +1.4%	$81.73 +12.9%	+168.8%	$6.39B	$5.07M	N/A	61	Positive News Upcoming Earnings Options Volume
ROIV Roivant Sciences	1.6524 of 5 stars	$33.84 -2.5%	$33.59 -0.7%	+197.5%	$24.34B	$8.26M	N/A	860	Positive News
BNTX BioNTech	4.0497 of 5 stars	$92.45 +1.5%	$129.13 +39.7%	-17.0%	$23.38B	$2.81B	N/A	7,807	Trending News Analyst Forecast
INSM Insmed	4.0717 of 5 stars	$104.13 -0.6%	$209.35 +101.0%	-11.3%	$22.57B	$606.42M	N/A	1,664	Positive News
MRNA Moderna	1.398 of 5 stars	$55.81 +0.3%	$40.00 -28.3%	+104.8%	$22.14B	$2.20B	N/A	4,700	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does CG Oncology compare to Roivant Sciences?

Summary

How does CG Oncology compare to BioNTech?

Summary

How does CG Oncology compare to Insmed?

Summary

How does CG Oncology compare to Moderna?

Summary

How does CG Oncology compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does CG Oncology compare to Roivant Sciences?

Which has more volatility & risk, ROIV or CGON?

Do analysts rate ROIV or CGON?

Do insiders and institutionals hold more shares of ROIV or CGON?

Does the media favor ROIV or CGON?

Is ROIV or CGON more profitable?

Which has stronger valuation & earnings, ROIV or CGON?

Summary

How does CG Oncology compare to BioNTech?

Do analysts rate BNTX or CGON?

Does the media favor BNTX or CGON?

Do institutionals and insiders believe in BNTX or CGON?

Which has stronger earnings and valuation, BNTX or CGON?

Is BNTX or CGON more profitable?

Which has more volatility & risk, BNTX or CGON?

Summary

How does CG Oncology compare to Insmed?

Do insiders & institutionals hold more shares of INSM or CGON?

Does the media favor INSM or CGON?

Is INSM or CGON more profitable?

Which has better valuation and earnings, INSM or CGON?

Which has more volatility & risk, INSM or CGON?

Do analysts recommend INSM or CGON?

Summary

How does CG Oncology compare to Moderna?

Does the media favor MRNA or CGON?

Do analysts recommend MRNA or CGON?

Which has higher earnings & valuation, MRNA or CGON?

Do institutionals and insiders hold more shares of MRNA or CGON?

Is MRNA or CGON more profitable?

Which has more volatility and risk, MRNA or CGON?

Summary

How does CG Oncology compare to Viatris?

Which has preferable earnings and valuation, CGON or VTRS?

Does the media favor CGON or VTRS?

Which has more volatility and risk, CGON or VTRS?

Do analysts prefer CGON or VTRS?

Is CGON or VTRS more profitable?

Do institutionals & insiders have more ownership in CGON or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools